Medscape April 3, 2024
(Reuters) -The U.S. health regulator approved Basilea Pharmaceutica’s antibiotic for bacterial infections including multidrug-resistant strains, the FDA said on Wednesday.
The Switzerland-based company was seeking approval of its antibiotic ceftobiprole for the treatment of three conditions – Staphylococcus aureus bacteremia (SAB), acute bacterial skin and skin structure infections, and community-acquired bacterial pneumonia.
The approval expands options for patients who may have developed a resistance to currently available antibiotics. More than 2.8 million antimicrobial-resistant infections occur each year in the U.S., according to government data.
The U.S. market for the intravenous antibiotic, which will be sold under the brand name Zevtera, is projected to be $5.50 billion and is probably going to be the “lion’s share of the market for this...
Today's Sponsors
Today's Sponsor